Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human BRCA2 Antikörper:
anti-Rat (Rattus) BRCA2 Antikörper:
anti-Mouse (Murine) BRCA2 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Monoclonal BRCA2 Primary Antibody für IHC, IHC (p) - ABIN445491
Wu, Jiang, Thangaraju, Wu, Couch: Induction of the BRCA2 promoter by nuclear factor-kappa B. in The Journal of biological chemistry 2000
Show all 2 Pubmed References
Human Monoclonal BRCA2 Primary Antibody für IHC, IHC (fro) - ABIN445493
Bernard-Gallon, Déchelotte, Vissac, Aunoble, Cravello, Malpuech, Bignon: BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite. in Breast cancer research : BCR 2001
Show all 2 Pubmed References
Human Polyclonal BRCA2 Primary Antibody für IHC, IHC (fro) - ABIN4285196
Moeller, Yordy, Williams, Giri, Raju, Molkentine, Byers, Heymach, Story, Lee, Sturgis, Weber, Garden, Ang, Schwartz: DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. in Clinical cancer research : an official journal of the American Association for Cancer Research 2011
The heterogeneity of the detected mutations confirms the necessity of simultaneous analysis of BRCA1/2 genes in all patients diagnosed with serous ovarian carcinoma. Moreover, the use of tumor tissue for mutational analysis allowed the detection of both somatic and germline BRCA1/2 mutations.
We demonstrated an association between six previously published single nucleotide polymorphisms (rs15869 [ BRCA2], rs1805389 [ LIG4 (zeige LIG4 Antikörper)], rs8079544 [ TP53 (zeige TP53 Antikörper)], rs25489 [ XRCC1 (zeige XRCC1 Antikörper)], rs1673041 [ POLD1 (zeige POLD1 Antikörper)], and rs11615 [ ERCC1 (zeige ERCC1 Antikörper)]) and subsequent CNS tumors in survivors of childhood cancer treated by radiation therapy.
Results show the overall prevalence of BRCA1/2 mutations at 3.9 % in the current large cohort of Chinese women with breast cancer, which is comparable with previous findings. Also, 41 % of the BRCA1/2 mutations detected have not been previously reported, suggesting that these mutations could be specific for Chinese women.
Patients with Fanconi anemia (zeige PALB2 Antikörper) have higher incidences of ectopic neurohypophysis, adenohypophysis hypoplasia, platybasia and other midline central nervous system skull base posterior fossa abnormalities than age- and sex-matched controls. Patients with posterior fossa abnormalities, including pontocerebellar hypoplasia, are more likely to have biallelic BRCA2 mutations.
CDNA representing BRCA2 alternate splice sites was amplified.
Pre-test genetic counselling prior to BRCA1/2 testing.
have confirmed previous reports of an association between breast, ovarian, and pancreatic cancers with BRCA1 and 2 mutations
Although no founder mutations were identified in this study, two recurrent mutations, BRCA1 (c.3607C>T) and BRCA2 (c.5164_5165 delAG), were found
The overall BRCA1/2 mutation prevalence was 24.0% (95% CI 23.4% to 24.6%).
observations indicate that nascent DNA degradation in BRCA1/2-deficient cells occurs as a consequence of MRE11 (zeige MRE11A Antikörper)-dependent nucleolytic processing of reversed forks generated by fork remodelers
persistent meiotic DNA double-strand breaks might correspond to crossovers, which are mobilized to the nuclear envelope for their repair; Brca2-Pds5 complexes may be key mediators of this process.
A mutation in Cyp6d2, a cytochrome P450 (zeige PHM Antikörper) gene, when combined with a brca2 mutation, resulted in synergistic hypersensitivity to camptothecin.
DNA repair by homologous recombination is dramatically decreased in CG30169 (brca2 homolog) mutants.
the data suggest for the first time that brca2/fancd1 is essential for vertebrate kidney ontogeny.
Carcinogenesis in zebrafish with combined mutations in tp53 (zeige TP53 Antikörper) and brca2 typically requires biallelic mutation or loss of at least one of these genes.
The novel role of Brca2 in organizing the vertebrate egg nucleus may provide new insights into the origin of ovarian cancer
critical roles for brca2 in ovarian development and tumorigenesis in reproductive tissues
we generated a Brca2 knock-in mouse model lacking exons 4-7 and demonstrated that these exons are dispensable for viability as well as tumor-free survival. This study provides the first in vivo evidence of the functional significance of a minor transcript of BRCA2 that can play a major role in the survival of humans who are homozygous for a clearly pathogenic mutation.
we describe a genetic approach to examine the functional significance of the interaction between BRCA2 and PALB2 (zeige PALB2 Antikörper) by generating a knock-in mouse model of Brca2 carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 (zeige PALB2 Antikörper) and Trp53 (zeige TP53 Antikörper) heterozygosity .
Merit40 (zeige BABAM1 Antikörper) mutation exacerbated ICL-induced chromosome instability in the context of concomitant Brca2 deficiency but not in conjunction with Fancd2 (zeige FANCD2 Antikörper) mutation.
Heterozygous and homozygous Brca2 mutation may lead to dysfunction in T cell populations.
BRCA2 exon 27 domain maintains chromosomal integrity at both stalled and collapsed replication forks consistent with involvement in both replication fork maintenance and double strand break repair.
we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several types of chemotherapy and PARP (zeige PARP1 Antikörper) inhibition.
BRCA2-mediated sequestration of nuclear RAD51 (zeige RAD51 Antikörper) serves to prevent inappropriate DNA interactions.
BRCA2 directly represses the expression of IFN-related genes
the models reveal novel aspects of cancer evolution in carriers of germline BRCA2 mutations, provide new insights into the tumour suppressive role of BRCA2
genetic stability, and hematopoietic differentiation potential of gene-corrected Brca2(Delta) (27/) (Delta) (27) iPSCs, achievements and limitations in the application of current reprogramming approaches in hematopoietic stem cell therapy are also discussed.
Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele.
BRCA1/BRCA2-containing complex, subunit 2
, breast and ovarian cancer susceptibility gene, early onset
, breast cancer 2 tumor suppressor
, breast cancer type 2 susceptibility protein
, fanconi anemia group D1 protein
, truncated breast and ovarian cancer susceptibility protein 2
, breast cancer 2, early onset homolog
, breast cancer 2, mutation 1, University of Wisconsin-Madison
, breast cancer susceptibility protein 2
, breast cancer type 2 susceptibility protein homolog
, fanconi anemia group D1 protein homolog
, breast and ovarian cancer susceptibility protein 2
, breast cancer 2, early onset
, breast cancer type 2 susceptibility protein-like